top of page
Our Story
Our Science
After several years of research, our network of scientists discovered Conjugated Psilocin (CP).
CP is the first stable and bioavailable form of psilocin now patented for use as a new drug candidate.





A second opportunity came about thru a late stage development product for the treatment of a rare genetic disorder called Sickle Cell Disease (SCD).
Altemia MF is our new medical food product designed to address the deficiencies of this long overlooked and under served patient population.


bottom of page